U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284654) titled 'Safety, Tolerability, and Immunogenicity of VAX-31 in Adults >=50 Years With Immunobridging to Adults 18-49' on Dec. 08.
Brief Summary: The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults >=50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Pneumococcal Vaccines
Intervention:
BIOLOGICAL: 31 valent pneumococcal conju...